Real-world effectiveness and tolerability of erenumab: A retrospective cohort study.
Saad KanaanGabrielle HettieElizabeth W LoderRebecca BurchPublished in: Cephalalgia : an international journal of headache (2020)
This large "real-world" study validates the findings of benefit of erenumab observed in clinical trials. Although adverse events were far more common in this population than in clinical trials, the planned continuation rate was relatively high. The substantial discrepancy between adverse events seen in clinical practice compared with clinical trials suggests systematic differences between clinical trial participants and patients who receive the treatment in clinical practice, or may indicate suboptimal ascertainment of adverse events in the trials. Clinicians should continue to be vigilant for adverse events in clinical practice.